Posts in new medicines
Imepitoin for noise aversion in dogs

Imepitoin, which is licensed as an antiepileptic for dogs under the brand name Pexion, is now also licensed “for the reduction of anxiety and fear associated with noise phobia in dogs” . In this module we examine the available evidence to find out how helpful imepitoin is in managing noise aversion in dogs. By doing this module you will:

  • understand the mode of action of imepitoin in reducing fear and anxiety

  • be aware of the clinical evidence in support of the new indication

  • understand how to use imepitoin for treating noise aversion in dogs

  • know the adverse effects of imepitoin in dogs treated for noise aversion.

Read More
Grapiprant – a new drug for treating osteoarthritis in dogs

By doing this module you will:

  • understand the pharmacology of grapiprant;

  • know the clinical evidence on the efficacy and safety of grapiprant;

  • be aware of what is known about how grapiprant compares with NSAIDs;

  • understand what is meant by intention-to-treat and per-protocol analysis in clinical trials result analysis;

  • understand what is meant by the number needed to treat and its relevance to clinical practice.

Read More
Tramadol for pain relief in dogs: what's its place? (Updated)

By doing this module you will:

  • understand the pharmacology of tramadol

  • know the evidence on its efficacy in acute and chronic pain

  • be aware of the adverse effects

  • know the place of tramadol in the management of pain in dogs.

Read More
Leptospira vaccines

By doing this module you will:

  • understand the naming system for Leptospira and the relevance to vaccination;

  • understand what is known about the types of Leptospira affecting dogs in the UK;

  • understand the features of the different vaccines and how they compare;

  • be aware of what is known about the safety of the vaccines';

  • be able to make a rational choice.

Read More
Lokivetmab – a new treatment for canine atopic dermatitis

Why do this module?

Lokivetmab is a new treatment for reducing the clinical signs of atopic dermatitis in dogs. It is also a new type of medicine (a monoclonal antibody) for the treatment of animals in the UK. This module explains about monoclonal antibodies, summarises what is known about the efficacy and safety of lokivetmab in the treatment of canine atopic dermatitis, and discusses where it might fit in the management of atopic dermatitis. 

Read More
Imepitoin for idiopathic epilepsy in dogs

Imepitoin is a drug that first became available in 2013 as a welcome new addition to the limited choice of drugs available for treating canine epilepsy. This is a summary of the evidence on imepitoin, including how it compares with alternatives, and the evidence behind promotional claims.

Read More
Post-operative pain in cats – meloxicam or robenacoxib?

A recent advert for the injectable NSAID, robenacoxib (Onsior – Novartis) says the drug gives “superior pain relief”, going on to say that “In a recent study Onsior injection demonstrated superior efficacy to meloxicam in reducing post-operative pain in cats”. The advert gives a web link to more information, including the claim that robenacoxib is “tissue selective” and “persists at the source of inflammation but exits the bloodstream quickly, sparing vulnerable organs from prolonged exposure”. Here, we look at the evidence behind these claims.

Read More